Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation.
The optimal management of Epstein-Barr virus (EBV)-induced post-transplant lymphoproliferative diseases (PTLD) remains controversial. While withdrawal or reduction of immunosuppression is widely accepted as the strategy for the treatment of EBV/PTLD, the role of additional therapeutic interventions remains less clear. Newer strategies, including anti-B-cell monoclonal antibodies and adoptive immunotherapy offer the promise of impaired efficacy and outcome against EBV disease, but lack data demonstrating how and when to use these approaches. The current review provides an overview of potential strategies and presents guidelines for the management of EBV/PTLD in solid-organ transplant recipients.
Green
M
M
University of Pittsburgh School of Medicine, Division of Allergy, Immunology and Infectious Diseases, Children's Hospital of Pittsburgh, PA 15213, USA. greenm@chplink.chp.edu
D001402:B-Lymphocytes / Q000276:immunology; D020031:Epstein-Barr Virus Infections / Q000145:classification / Q000209:etiology / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007167:Immunotherapy / Q000379:methods; D008232:Lymphoproliferative Disorders / Q000145:classification / Q000209:etiology / Q000628:therapy*; D016377:Organ Transplantation / Q000009:adverse effects*; D011183:Postoperative Complications / Q000821:virology*; D014181:Transplantation Immunology
D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents